Qinghai Spring Medicinal Resources Technology Co., Ltd.

Shanghai Stock Exchange 600381.SS

Qinghai Spring Medicinal Resources Technology Co., Ltd. EBITDA Margin for the year ending December 31, 2023: -108.39%

Qinghai Spring Medicinal Resources Technology Co., Ltd. EBITDA Margin is -108.39% for the year ending December 31, 2023, a 25.21% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Qinghai Spring Medicinal Resources Technology Co., Ltd. EBITDA Margin for the year ending December 31, 2022 was -144.94%, a -3.51% change year over year.
Qinghai Spring Medicinal Resources Technology Co., Ltd. EBITDA Margin for the year ending December 31, 2021 was -140.03%, a -919.52% change year over year.
Qinghai Spring Medicinal Resources Technology Co., Ltd. EBITDA Margin for the year ending December 31, 2020 was 17.09%, a 93.08% change year over year.
Qinghai Spring Medicinal Resources Technology Co., Ltd. EBITDA Margin for the year ending December 31, 2019 was 8.85%, a -73.68% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Shanghai Stock Exchange: 600381.SS

Qinghai Spring Medicinal Resources Technology Co., Ltd.

CEO	Mr. Xuefeng Zhang
IPO Date	May 8, 2001
Location	China
Headquarters	Xining Eco and Techn Dev Zone
Employees	173
Sector	Materials
Industries Paper & Forest Products Biotechnology Pharmaceuticals

Description

Qinghai Spring Medicinal Resources Technology Co., Ltd. research and development, production, and sale of cordyceps products. It is also involved in the sale of beverages and aquatic products; advertising; and foreign investment business. The company was founded in 2003 and is based in Xining, China.

Key trends

Past 5 years